Biotech ETF IBB is on pace for its fourth positive session in the last five. CNBC's David Faber reports.
Wall Street has IPO fever, and Renaissance Capital principal Kathleen Smith says healthy demand for these upstarts should keep the market red-hot this year.
Pfizer's deal to buy Array BioPharma for $10.6 billion has ignited biotech stocks. There are ways to get in on the rally using exchange-traded funds.
Kathleen Smith of Renaissance Capital joins Bob Pisani to discuss her firm's IPO-oriented ETF that is trouncing the broader market in 2019.
Chris Hempstead of Deutsche Bank and Nancy Davis of Quadratic Capital talk low-volatility ETFs as uncertainty around U.S. trade policy and the Fed's next move grips the market.
Chris Hempstead of Deutsche Bank and Nancy Davis of Quadratic Capital join Bob Pisani to discuss low-volatility ETFs. Kathleen Smith of Renaissance Capital also joins to talk about her fund's IPO-oriented ETF.
Biotech stocks are on the move ahead after Pfizer announced it was acquiring Array BioPharma. Nancy Davis of Quadratic Capital and Chris Hempstead of Deutsche Bank join CNBC's Bob Pisani to discuss the ETFs to watch.
CNBC's Mike Santoli discusses the difference between quality stocks and value stocks, and which are performing better in the market.
Transparency is key… or is it? With the first-ever non-transparent, actively managed exchange-traded fund receiving approval from the SEC, "ETF Edge" goes straight to the source with the man behind the new product.
CNBC's Sara Eisen and Carl Quintanilla take a look at the chip sector as it plunges on weak earnings from Broadcom.
CNBC's Wilfred Frost takes a look at semiconductors as the sector slumps after four straight days in gains.
CNBC's Mike Santoli takes a look at what a comeback in the market looks like for the major indices.
Exchange-traded funds focused on e-commerce are the way to play the retail sector without getting burned, some experts say.
ETFs with heavy exposure to Mexico are popping on the Trump administration's deal to avoid tariffs, but experts preach selectivity.
Stuart Thomas of Precidian Investments joins Bob Pisani to talk about the SEC's first-ever approval of an exchange-traded fund that doesn't share its portfolio changes every day.
Christian Magoon of Amplify ETFs and Tom Lydon of ETFTrends.com discuss the performance of exchange-traded funds with the highest exposure to Mexico with host Bob Pisani.
Tom Lydon of ETFTrends.com and Christian Magoon of Amplify ETFs break down the latest trends in the ETF space with host Bob Pisani. With special guest Stuart Thomas of Precidian Investments.
Christian Magoon, Amplify ETFs, and Tom Lydon, ETFTrends.com, join 'ETF Edge' to discuss the bright spots in the retail sector with CNBC's Bob Pisani.
In an era of rapid technological advances and demographic change, how do legacy companies adapt, innovate and evolve? CNBC Evolve features iconic global companies and executives who are embracing change and transforming for the future.
Invest in You: Ready. Set. Grow. is focused on improving Americans’ money knowledge of saving, spending and investing.
All the tools you need to navigate the financial challenges of planning and paying for college.